Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927198 · ClinicalTrials.gov registry record · Phase 2
RDEA3170 Monotherapy in Subjects With Gout
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT01927198 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 172 participants.
The verdict
NCT01927198, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
Interventions
- DRUG Placebo
- DRUG RDEA3170 5 mg
- DRUG RDEA3170 10 mg
- DRUG RDEA3170 12.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927198
The ClinicalTrials.gov registry entry for NCT01927198 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01927198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927198 about?
NCT01927198 is a clinical study titled "RDEA3170 Monotherapy in Subjects With Gout". This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
What is the current status of trial NCT01927198?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2013-08. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01927198?
The interventions under investigation include: Placebo (DRUG), RDEA3170 5 mg (DRUG), RDEA3170 10 mg (DRUG), RDEA3170 12.5 mg (DRUG).
Who is sponsoring clinical trial NCT01927198?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.